Cargando…
An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies
The use of monoclonal antibodies has expanded beyond the realm of autoimmune disease and cancer therapeutics to communicable diseases. Their antiviral activities were evaluated in some diseases such as SARS MERS (Middle East Respiratory Syndrome) and Ebola. In recent times, antispike SARS-CoV-2 mono...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012417/ https://www.ncbi.nlm.nih.gov/pubmed/35343208 http://dx.doi.org/10.4103/ijp.ijp_519_21 |
_version_ | 1784687791870836736 |
---|---|
author | Chatterjee, Suparna Choudhury, Shouvik Das, Debaleena |
author_facet | Chatterjee, Suparna Choudhury, Shouvik Das, Debaleena |
author_sort | Chatterjee, Suparna |
collection | PubMed |
description | The use of monoclonal antibodies has expanded beyond the realm of autoimmune disease and cancer therapeutics to communicable diseases. Their antiviral activities were evaluated in some diseases such as SARS MERS (Middle East Respiratory Syndrome) and Ebola. In recent times, antispike SARS-CoV-2 monoclonal antibody cocktails (casirivimab with imdevimab and bamlanivimab with etesevimab) and single agent sotrovimab have received emergency use authorization for treatment of nonhospitalized COVID-19 patients with mild-to-moderate disease at high risk of disease progression. This review summarizes their mechanism of action, salient pharmacokinetic profile, safety and clinical trial (ongoing and completed) data. Despite evidence to support its use for the indication, the high cost of these biologics may make it unaffordable for many patients, but further clinical studies on their cost-benefit profile shall provide useful information to the scientific community and patients. |
format | Online Article Text |
id | pubmed-9012417 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-90124172022-04-16 An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies Chatterjee, Suparna Choudhury, Shouvik Das, Debaleena Indian J Pharmacol Review Article The use of monoclonal antibodies has expanded beyond the realm of autoimmune disease and cancer therapeutics to communicable diseases. Their antiviral activities were evaluated in some diseases such as SARS MERS (Middle East Respiratory Syndrome) and Ebola. In recent times, antispike SARS-CoV-2 monoclonal antibody cocktails (casirivimab with imdevimab and bamlanivimab with etesevimab) and single agent sotrovimab have received emergency use authorization for treatment of nonhospitalized COVID-19 patients with mild-to-moderate disease at high risk of disease progression. This review summarizes their mechanism of action, salient pharmacokinetic profile, safety and clinical trial (ongoing and completed) data. Despite evidence to support its use for the indication, the high cost of these biologics may make it unaffordable for many patients, but further clinical studies on their cost-benefit profile shall provide useful information to the scientific community and patients. Wolters Kluwer - Medknow 2022 2022-03-18 /pmc/articles/PMC9012417/ /pubmed/35343208 http://dx.doi.org/10.4103/ijp.ijp_519_21 Text en Copyright: © 2022 Indian Journal of Pharmacology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Review Article Chatterjee, Suparna Choudhury, Shouvik Das, Debaleena An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies |
title | An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies |
title_full | An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies |
title_fullStr | An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies |
title_full_unstemmed | An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies |
title_short | An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies |
title_sort | update of antispike severe acute respiratory syndrome coronavirus 2 (sars-cov-2) monoclonal antibodies |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012417/ https://www.ncbi.nlm.nih.gov/pubmed/35343208 http://dx.doi.org/10.4103/ijp.ijp_519_21 |
work_keys_str_mv | AT chatterjeesuparna anupdateofantispikesevereacuterespiratorysyndromecoronavirus2sarscov2monoclonalantibodies AT choudhuryshouvik anupdateofantispikesevereacuterespiratorysyndromecoronavirus2sarscov2monoclonalantibodies AT dasdebaleena anupdateofantispikesevereacuterespiratorysyndromecoronavirus2sarscov2monoclonalantibodies AT chatterjeesuparna updateofantispikesevereacuterespiratorysyndromecoronavirus2sarscov2monoclonalantibodies AT choudhuryshouvik updateofantispikesevereacuterespiratorysyndromecoronavirus2sarscov2monoclonalantibodies AT dasdebaleena updateofantispikesevereacuterespiratorysyndromecoronavirus2sarscov2monoclonalantibodies |